Background {#Sec1}
==========

Tobacco smoking is a multi-factorial behavior with both genetic and environmental determinants \[[@CR1]\]. Genetic factors have a greater influence on smoking cessation than do environmental factors \[[@CR2]\]. Genetic factors are responsible for 30--50% of the variance in the risk of withdrawal symptoms, 40--75% of the variation in smoking initiation, 50% of the variance in cessation success, and 70--80% of the variation in smoking maintenance \[[@CR1]\]. Genetic risk information enhances the motivation for smoking cessation \[[@CR3]\]. Therefore, assessment of genetic background could be a promising tool to understand smoking risk and to guide the selection of the most effective cessation treatment for an individual smoker.

Nicotine is the major psychoactive ingredient in tobacco, and it modulates dopamine activity in the midbrain, which contributes to the development and maintenance of rewarding behaviors such as smoking \[[@CR4]\]. Smokers modulate their smoking to maintain brain nicotine levels within a certain concentration range, and factors that alter nicotine clearance affect smoking behavior \[[@CR4]\]. Individuals who eliminate nicotine rapidly are less likely to achieve low craving scores even after smoking freely \[[@CR4]\]. Consequently, genetic polymorphisms in both nicotine metabolism and dopamine catabolism genes influence smoking status, interact with each other to result in risk modulation, and affect smoking cessation therapies.

The cytochrome P450 (*CYP*) 2A6 gene, located on chromosome 19q12-q13.2, consists of nine exons. It is involved in producing a 494-amino-acid protein that oxidizes coumarin, nicotine, and tobacco-specific nitrosamines \[[@CR5]\]. *CYP2A6* is the primary human enzyme involved in nicotine metabolism \[[@CR4]\]. *CYP2A6* catalyzes the C-oxidation of nicotine to the inactive metabolite cotinine and the subsequent conversion of cotinine into trans-3′-hydroxycotinine \[[@CR4]\]. *CYP2A6* is the most studied enzyme involved in both adult and adolescent smokers \[[@CR6]\]. The results of studies among Taiwanese individuals indicate that the variant status of *CYP2A6* is different from that among other ethnic groups \[[@CR7]\]. Therefore, we hypothesized that, for Taiwanese individuals, polymorphisms in the *CYP2A6* gene that affect smoking status could be different from those in other ethnic groups.

The catechol-*O*-methyltransferase (*COMT)* gene is located on chromosome 22q11.21, has eight exons, and produces a 271-amino-acid protein that metabolizes catecholamines \[[@CR8]\]. Low enzyme activity of the Met allele at codon 108/158 (in the rs4680 polymorphism) of the *COMT* gene, which encodes a key enzyme involved in the metabolic inactivation of dopamine, has been associated with nicotine dependence \[[@CR9]\]. Another polymorphism of *COMT*, rs165599, has been related to the response to bupropion therapy for smoking cessation \[[@CR10]\]. However, those associations have been inconsistent among ethnic groups \[[@CR10], [@CR11]\]. Thus, it seems necessary to perform a genetic study of smoking status for each ethnicity.

Smoking addiction is currently a significant social problem in Taiwan \[[@CR12]\]. Nonetheless, very few genetic investigations of nicotine--dopamine metabolism and smoking status among Taiwanese individuals have been performed. Recently, for Taiwanese smokers in a group of methadone maintenance patients, polymorphisms of the μ-opioid receptor gene were associated with the plasma concentration of cotinine \[[@CR13]\]. Very recently, our team reported that the interaction of the dopamine D2 receptor (*DRD2*) TaqIB and monoamine oxidase A (*MAOA*) affected smoking intensity in young men \[[@CR14]\]. Those findings encouraged us to perform more genetic studies of Taiwanese smokers. In relation to nicotine--dopamine metabolism, smoking status has been reported to correlate better with some gene--gene interactions than with a single gene only. These interactions include *COMT* and *MAOA* \[[@CR15], [@CR16]\], *MAOA* and *CYP2A6* \[[@CR17]\], *CYP2A6* and the nicotine acetylcholine receptor gene \[[@CR18], [@CR19]\], and *CYP 2A6* and *DRD2* TaqIA \[[@CR20]\]. However, the effects of *CYP2A6* and *COMT* together have not been explored, and we hypothesized that a single polymorphism as well as an interaction of the two genes could be involved in smoking status.

In women not using oral contraceptives, nicotine and cotinine clearance is 13 and 24% higher, respectively, than in men \[[@CR6]\]. Sex differences exist for cravings, affect, and preference for immediate smoking after cue exposure \[[@CR21]\]. Because Taiwanese men smoke significantly more cigarettes than Taiwanese women \[[@CR12], [@CR22]\], only men were invited to participate in our study. In this study, the polymorphisms *CYP2A6*\*1A (wild-type), *CYP 2A6*\*1B (polymorphism of faster nicotine clearance) \[[@CR23]\], *CYP2A6*\*4C (the most studied polymorphism of decreased nicotine metabolism) \[[@CR24]\], *COMT* Val/Met (rs4680) \[[@CR9]\], and *COMT* rs165599 \[[@CR10]\] were determined. Our objectives were to investigate the effects of the interaction between the *CYP 2A6* and *COMT* genes and their association with smoking risk in young Taiwanese men.

Methods {#Sec2}
=======

Participants and procedures {#Sec3}
---------------------------

This cross-sectional study was advertised to all students at both Chang Jung Christian University and Central Taiwan University of Science and Technology. The volunteers contacted the authors of the study, and convenience samples were then screened for eligibility at the health centers of the two universities. All study subjects provided written, informed consent at the beginning of study, and the study was approved by the review board of Chang Jung Christian University (CJCU-99004) and Central Taiwan University of Science and Technology (CTUST-99016). The study was conducted in accordance with Good Clinical Practice procedures and the Declaration of Helsinki.

We administered a self-report questionnaire to all of the study subjects \[[@CR25]--[@CR27]\]. The questionnaire included demographic data, smoking background and status. In addition, the questionnaire included the fagerstrom test for nicotine dependence (six-item FTND) \[[@CR25]\], the 15-item short form of the Physiological Cigarette Dependence Scale (PCDS) derived from the 30-item PCDS \[[@CR27]\], and the Withdrawal Symptoms Scale (Cigarette Withdrawal Scale, CWS-21) \[[@CR26], [@CR27]\]. These questionnaires used biomarkers (nicotine and cotinine concentrations) as validation, with no over- or under-exaggeration. Never smokers were defined as persons who had never smoked in their lifetime. Current smoking was defined as ever smoking cigarettes on 1 or more days of the past 30 days. Ever smokers were defined as persons who smoked at one time, had quit, and were not currently smoking. The current smokers were divided into two groups according to their intensity of cigarette smoking: light smokers and heavy smokers, depending on number of cigarettes per day lower than or equal to (or higher than) the average value of all the smokers, respectively. The exclusion criteria were (1) a history of diagnosed mental health disease or cancer, (2) alcoholism or drug abuse, (3) severe communication problems, or (4) terminal illness. When the survey was completed, blood and urine samples were obtained at a university center by trained research assistants (licensed nurses or medical technologists).

Determination of CYP2A6 and COMT polymorphisms {#Sec4}
----------------------------------------------

In this study, to determine the genotypes of the variants of interest, total genomic DNA was isolated from blood cells using a blood DNA isolation kit (Favorgen, Ping-Tung, Taiwan). Five milliliters of whole blood with EDTA as an anticoagulant were required. Approximately 40 alleles of the *CYP2A6* gene have been identified \[[@CR28]\]. However, only the wild-type (*CYP2A6*\*1A) and two highly prevalent (\>10%) variants of *CYP2A6*\*1B (approximately 45%) \[[@CR29]\] and *CYP2A6*\*4C (approximately 15%) \[[@CR30]\], which have been observed in Chinese individuals, were determined in this project.

The polymorphisms of *CYP2A6* were identified using polymerase chain reaction-restriction fragment length polymorphism (PCR--RFLP) \[[@CR31]\]. We designed the forward primer 5′-CACCGAAGTGTTCCCTATGCTG-3′ and reverse primer 5′-TGTAAAATGGGCATGAACGCCC-3′ according to the GenBank accession system. PCR was performed with a thermal cycler (Bio-Rad, Carlsbad, CA, USA). The PCR conditions were as follows: first cycle, denaturation at 94 °C for 3 min; cycles 2--31, denaturation at 94 °C for 1 min, annealing at 55 °C for 1 min, and elongation at 72 °C for 2 min, with a final extension for 7 min at 72 °C. We detected a 1332-base pair (bp) fragment on a 1% agarose gel after electrophoresis at 100 V for 60 min. Using *BstU*-*I* as the restriction enzyme, one (1332-bp) and two (291 and 1041-bp) fragments were obtained for *CYP2A6*\*1A and *CYP2A*6\*non-1A, respectively. Using the restriction enzyme *Bsu36*-*I*, three fragments (104, 437, and 792-bp) were observed for *CYP2A6*\*1A or *CYP2A6*\*1B. Four fragments (64, 104, 437, and 728-bp) were found for *CYP2A6*\*4C. Positive controls were run for each of the genotyping assays. The DNAs of *CYP2A6*\*1A/\*1A, *CYP2A6*\*1A/\*1B, *CYP2A6*\*1B/\*1B, *CYP2A6*\*1A/\*4C, and *CYP2A6*\*1B/\*4C, which have been found in Taiwanese and Chinese populations, were identified by DNA sequencing \[[@CR29], [@CR30]\]. Additional file [1](#MOESM1){ref-type="media"}: Table S1 lists the result.

For *COMT* rs4680, the forward primer 5′-CTGTGGCTACTCAGCTGTG-3′ and reverse primer 5′-CCTTTTTCCAGGTCTGACAA-3′ were used to amplify a 169-bp fragment \[[@CR10]\]. Using *N1a III* as the restriction enzyme, three (114, 32, and 23-bp), four (96, 32, 23, and 18-bp), and five (114, 96, 32, 23, and 18-bp) fragments were obtained for the G/G, A/A, and G/A genotypes, respectively \[[@CR10]\]. For COMT rs165599, the forward primer 5′-CATTCAAAGCTCCCCTTGAC-3′ and reverse primer 5′-GGGAGTAGG-GAAGGAGATGC-3′ were utilized to amplify a 301-bp fragment \[[@CR32]\]. Using *Msp I* as the restriction enzyme, one (301-bp), two (166 and 135-bp), and three (301, 166, and 135-bp) fragments were obtained from the A/A, G/G, and A/G genotypes, respectively \[[@CR32]\].

Determination of urinary nicotine and cotinine {#Sec5}
----------------------------------------------

To evaluate the effects of genetic polymorphisms on the metabolism of nicotine and cotinine, urinary nicotine and cotinine levels of smokers were measured. Gas chromatography--mass spectrometry (GC/MS) was performed as previously described \[[@CR33]\], with the following difference: GC--MS analyses were performed on a ThermoElectron DSQII quadrupole mass spectrometer connected directly to a ThermoElectron focus gas chromatograph and an autosampler AS 3000 (Thermo Electron Corporation, Dreieich, Germany). All urine samples were stored at −20 °C before analysis. All of the analyses were performed in duplicate and repeated if values differed by \>10%. Tobacco cigarettes currently smoked in Taiwan contain 0.57--0.64 mg of nicotine per cigarette on average \[[@CR12]\]. The nicotine and cotinine concentrations in the urine of each subject were divided by the number of daily cigarettes smoked and defined as the adjusted nicotine and adjusted cotinine concentration.

The effects of gene polymorphism interactions on smoking behaviors {#Sec6}
------------------------------------------------------------------

The *CYP2A6* genotypes consisted of wild-type (\*1A/\*1A), high -activity (\*1A/\*1B and \*1B/\*1B), and low-activity (\*1A/\*4C, \*1B/\*4C, and \*4C/\*4C) genotypes. The *COMT* rs4680 genotypes consisted of wild-type (G/G) and variant (G/A and A/A). The *COMT* rs165599 genotypes consisted of wild-type (A/A) and variant (A/G and G/G) genotypes. To assess the interaction between the effects of *CYP2A*6 and *COMT* gene polymorphisms on smoking behaviors, multiple models were used to analyze the *CYP2A6*, *COMT* rs4680, and *COMT* rs165599 data: (1) single gene (model 1: *CYP2A*6) or single SNP (model 2: *COMT* rs4680, *COMT* rs165599, respectively); (2) 2 SNPs (model 3: *COMT* rs4680 and *COMT* rs165599); and (3) multiple genes (models 4--7). We evaluated the effect of the interactions between different gene combinations on smoking status (Table [2](#Tab2){ref-type="table"}), smoking intensity (Additional file [2](#MOESM2){ref-type="media"}: Table S2), nicotine dependence (FTND), physiological cigarette dependence (PCDS), nicotine toxicity and withdrawal symptoms (CWS-21) (Additional file [3](#MOESM3){ref-type="media"}: Table S3), and urine nicotine/cotinine concentration (Table [3](#Tab3){ref-type="table"}) in young men.

Statistical analysis {#Sec7}
--------------------

To evaluate the effect of the genetic variants on smoking status and smoking intensity, this study assigned an odds ratio (OR) as 1 to subjects carrying the wild-type. The Mantel--Haenszel Chi square test was utilized to calculate the ORs and their 95% confidence intervals (CIs) (Table [2](#Tab2){ref-type="table"}; Additional file [2](#MOESM2){ref-type="media"}: Table S2). To compare the significance of FTND, PCDS, and CWS-21 and to compare the urinary nicotine and cotinine clearance among subjects carrying different *CYP2A6* and *COMT* polymorphisms, Student's *t* test or analysis of variance (ANOVA), as appropriate, was applied to compare quantitative data. A P value of \<0.05 was defined as statistically significant for each analysis (Additional file [3](#MOESM3){ref-type="media"}: Table S3). When the result of ANOVA was statistically significant, multiple comparisons were followed by application of Scheffé's post hoc test. However, if the data in any group did not fit a normal distribution, the Mann--Whitney U test with Bonferroni adjustment was utilized to compare the data between the two groups (Table [3](#Tab3){ref-type="table"}). All data were analyzed using SPSS (version 18.0 software for Windows, SPSS Inc., Chicago, IL).

Results {#Sec8}
=======

We recruited a total of 500 men aged 20--25 years. Analysis of the questionnaires revealed that there were 219 never smokers, 261 current smokers, and 20 ever smokers. Due to the small sample size (moderate power analysis in general, α = 0.05 and 80% power requires 200 samples), the 20 ever smokers were excluded from further study. Mean age did not differ between the 261 current smokers and the 219 never smokers (22.6 ± 1.69 vs. 22.4 ± 1.42, *t* = 1.371, P = 0.176, data not shown).

The distributions of *CYP2A6* and *COMT* polymorphisms are shown in Table [1](#Tab1){ref-type="table"}. Using the frequencies of *CYP2A6*\*1A/\*1A, *CYP2A6*\*1A/\*1B, and *CYP2A6*\*1B/\*1B as examples, the distributions of *CYP2A6* genotypes agreed with Hardy--Weinberg equilibrium: P = 0.713 and 0.332 for current smokers and never smokers, respectively. The distribution of *COMT* rs165599 genotypes also agreed with Hardy--Weinberg equilibrium: P = 0.966 and 0.668 for current smokers and never smokers, respectively. The distribution of *COMT* rs4680 genotypes did not agree with Hardy--Weinberg equilibrium: P = 0.003 and 0.012 for current smokers and never smokers, respectively.Table 1Distribution of CYP2A6 and COMT polymorphismsGenotypesCurrent smokers \[n = 261 (n%)\]Hardy--Weinberg equilibriumNever smokers \[n = 219 (n%)\]Hardy--Weinberg equilibriumCYP2A6P^a^ = 0.713P^a^ = 0.3321A/1A63 (24.1)46 (21.0)1A/1B100 (38.3)88 (40.2)1B/1B44 (16.9)31 (14.2)1A/4C24 (9.2)25 (11.4)4C/4C4 (1.5)3 (1.37)1B/4C26 (10.0)26 (11.9)COMT rs4680P^b^ = 0.003P^b^ = 0.012G/G147 (56.3)113 (51.6)G/A73 (28.0)69 (31.5)A/A41 (15.7)37 (16.9)COMTrs165599P^c^ = 0.966P^c^ = 0.668A/A61 (23.4)45 (20.6)A/G130 (49.8)112 (51.1)G/G70 (26.8)62 (28.3)^a^For CYP2A6 1A/1A, 1A/1B, 1B/1B^b^For COMT rs4680^c^For COMT rs165599

As shown in Table [2](#Tab2){ref-type="table"}, after using never smokers as the reference group, the OR was significantly lower in the subjects carrying the genotype of *CYP2A6* low activity/variant *COMT* rs4680 than in those possessing the genotype of *CYP2A6* wild-type/variant *COMT* rs4680 (0.44, 95% CI 0.19--0.98, P = 0.043). The other 14 ORs were not statistically significant (P = 0.078--0.988).Table 2Odds ratios for the effects of *CYP2A6* and *COMT* polymorphisms on smoking statusGenotypes interactionCurrent smokers N = 261Never smokers N = 219OR (95% CI)P^a^Model 1 CYP2A6  Wild type63461.0  High activity1441190.88 (0.56--1.39)0.591  Low activity54540.73 (0.43--1.25)0.249Model 2 COMT  COMT rs4680   Wild type1471131.0   Variant1141060.83 (0.58--1.19)0.301  COMT rs165599   Wild type61451.0   Variant2001740.85 (0.55--1.31)0.458Model 3 COMT rs4680/COMT rs165599  Wild type/wild type27131.0  Wild type/variant1201000.58 (0.28--1.18)0.128  Variant/wild type34320.51 (0.23--1.16)0.107  Variant/variant80740.52 (0.25--1.08)0.078Model 4 COMT rs4680 wild type  CYP2A6 wild type35251.0  CYP2A6 high activity76650.84 (0.45--1.54)0.563  CYP2A6 low activity36231.12 (0.54--2.33)0.765Model 5 COMT rs4680 variant  CYP2A6 wild type28211.0  CYP2A6 high activity68540.94 (0.48--1.84)0.867  CYP2A6 low activity18310.44 (0.19--0.98)0.043Model 6 COMT rs165599 wild type  CYP2A6 wild type1581.0  CYP2A6 high activity33300.59 (0.22--1.58)0.289  CYP2A6 low activity1370.99 (0.28--3.48)0.988Model 7 COMT rs165599 variant  CYP2A6 wild type48381.0  CYP2A6 high activity111890.99 (0.59--1.64)0.961  CYP2A6 low activity41470.69 (0.38--1.26)0.224^a^Mantel--Haenszel Chi square testThe genotypes of (1) CYP2A6: wild-type (\*1A/\*1A), high activity (\*1A/\*1B and \*1B/\*1B), low activity (\*1A/\*4C, \*1B/\*4C, and \*4C/\*4C); (2) COMT rs4680: wild-type (G/G), variant (G/A and A/A); and (3) COMT rs165599: wild-type (A/A), variant (A/G and G/G)

The average number of cigarettes per day among the 261 current smokers was 10. There were 127 heavy smokers and 131 light smokers (data for three smokers were missing). With light smokers as the reference group, 15 ORs for heavy smoking were not statistically significant (P = 0.061--0.112, data in Additional file [2](#MOESM2){ref-type="media"}: Table S2).

For the 261 current smokers, FTND, PCDS, and CWS-21 were analyzed for 181, 227, and 210 subjects, respectively, because of missing data. Each of the eight comparisons for FTND, PCDS, and CWS-21 among the groups with different *CYP2A6/COMT* polymorphisms was not significantly different (P = 0.224--0.911, 0.054--0.700, and 0.075--0.836, respectively) (data in Additional file [3](#MOESM3){ref-type="media"}: Table S3).

Of the 261 current smokers, 122 subjects provided urine samples for the determination of nicotine and cotinine levels by GC/MS. The values for adjusted nicotine concentration and adjusted cotinine concentration were not normally distributed in either genotype group. The SD was too high: near the mean value or even greater than the mean value. Therefore, the Mann--Whitney U test or Kruskal--Wallis test with Bonferroni adjustment was used for comparison of the values of adjusted nicotine concentration and adjusted cotinine concentration between groups carrying different genotypes. As shown in Table [3](#Tab3){ref-type="table"}, the adjusted urinary nicotine concentration did not differ significantly in any of the comparisons. The median adjusted urinary cotinine concentration differed between the *COMT* rs4680 wild-type group and the *COMT* rs4680 variant group (92.46 ng/μL vs. 118.24 ng/μL, P = 0.041) and between the *COMT* rs4680 wild-type/*COMT* rs165599 variant group and the *COMT* rs4680 variant/*COMT* rs165599 variant group (97.10 ng/μL vs. 122.18 ng/μL, P = 0.022). The other comparisons were not statistically significant.Table 3Comparisons of adjusted urinary nicotine concentration and adjusted urinary cotinine concentration among subjects (N = 122) carrying different CYP2A6 and COMT polymorphismsNAdjusted urinary nicotine, ng/μL median (min--max)Adjusted urinary cotinine, ng/μL median (min--max)Model 1 CYP2A6  Wild type1786.23 (6.14--296.36)120.90 (20.39--485.32)  High activity7670.45 (6.28--1117.87)111.08 (8.34--822.11)  Low activity2961.59 (15.28--456.87)75.87 (10.87--266.44)  P^a^NSNSModel 2 COMT  COMT rs4680   Wild type6663.86 (6.28--646.38)92.46 (8.34--506.97)   Variant5667.87 (6.14--1117.87)118.24 (13.59--822.11)   P^a^NS0.041  COMT rs165599   Wild type2768.10 (12.42--212.74)89.42 (23.06--218.62)   Variant9564.11 (6.14--1117.87)107.24 (8.34--822.11)   P^a^NSNSModel 3 COMT rs4680/COMT rs165599  Wild type/wild type1389.29 (12.42--212.74)79.37 (23.06--218.62)  Wild type/variant5363.61 (6.28--646.38)97.10 (8.34--506.97)\*  Variant/wild type1467.87 (15.28--177.61)95.86 (32.18--202.0)  Variant/variant4269.46 (6.14--1117.87)122.18 (13.59--822.11)\*  P^a^NSModel 4 COMT rs4680 wild type  CYP2A6 wild type995.04 (25.04--296.36)105.70 (53.48--485.32)  CYP2A6 high activity3972.99 (6.28--646.38)97.45 (8.34--506.97)  CYP2A6 low activity1842.54 (19.38--371.29)60.20 (10.87--266.44)  P^a^NSNSModel 5 COMT rs4680 variant  CYP2A6 wild type874.91 (6.14--217.41)141.53 (20.39--228.68)  CYP2A6 high activity3768.10 (17.68--1117.87)115.78 (13.59--822.11)  CYP2A6 low activity1166.13 (15.28--456.87)161.65 (39.19--224.53)  P^a^NSNSModel 6 COMT rs165599 wild type  CYP2A6 wild type395.04 (62.36--188.57)102.30 (79.37--120.90)  CYP2A6 high activity1767.64 (12.42--212.74)89.42 (32.18--218.62)  CYP2A6 low activity778.05 (15.28--177.61)63.55 (23.06--202.00)  P^a^NSNSModel 7 COMT rs165599 variant  CYP2A6 wild type1474.92 (6.14--296.36)141.53 (20.39--485.32)  CYP2A6 high activity5972.99 (6.28--1117.87)111.09 (8.34--822.11)  CYP2A6 low activity2259.62 (19.38--456.87)81.66 (10.87--266.44)  P^a^NSNS*NS* not statistically significant^**a**^Mann--Whitney U test or Kruskal--Wallis test with Bonferroni adjustment\* Significantly different from the (COMT rs4680 wild-type/COMT rs165599 variant) group versus the (COMT rs4680 variant/COMT rs165599 variant) group by Scheffe's Post hoc test, P value = 0.022

Discussion {#Sec9}
==========

All subjects in this study were young adult university students. Alcohol and drug abusers were excluded. Therefore, the effects of age, education status and alcohol and drug interactions on smoking were absent.

Our results show that the distribution of *COMT* rs4680 does not agree with Hardy--Weinberg equilibrium, consistent with reports that Asiatic individuals have Hardy--Weinberg disequilibrium of the *COMT* rs4680 polymorphism \[[@CR8]\]. The main finding of this study is that among adult males with variant *COMT* rs4680, the subjects carrying the low-activity genotype of *CYP2A6* have a 0.44-fold lower risk of starting smoking than those possessing the wild-type genotype of *CYP2A6*. In other words, the OR is 2.27-fold higher in subjects carrying the *CYP2A6* wild-type/variant *COMT* rs4680 genotype than in those possessing the *CYP2A6* low activity/variant *COMT* rs4680 genotype. The *CYP2A6* and *COMT* genes were reported to be associated with smoking status. *CYP2A6*\*4C is a whole-deletion type, decreased nicotine metabolism polymorphism \[[@CR34]\]. In Japanese adults and young Japanese students, the frequency of the *CYP2A6*\*4C gene was significantly higher among non-smokers than smokers \[[@CR34], [@CR35]\]. Among Chinese males, participants with the *CYP2A6*\*4C genotype had a lower risk of smoking initiation and smoking persistence than those with the *CYP2A6*\*1/*CYP2A6*\*1 genotype \[[@CR17]\]. For people living in southern China, reduced metabolic function of *CYP2A6* in smokers appears to be associated with fewer cigarettes smoked, later initiation of smoking regularly, shorter smoking duration, and lower likelihood of smoking cessation \[[@CR36]\]. For Caucasian individuals, the *CYP2A6* slow inactivator genotype increased the risk of nicotine dependence when smoking was initiated during adolescence. However, it reduced the risk of smoking initiation, lowered cigarette consumption, and decreased the duration of smoking among adult dependent smokers \[[@CR37]\]. The continued effect of slow metabolism on reducing cigarette consumption, throughout the smoking history of people with *CYP2A6* slow inactivators, may affect tolerance and withdrawal mechanisms among these individuals \[[@CR37]\]. Smokers with *CYP2A6* slow inactivators smoke fewer cigarettes and tend to be less dependent on nicotine than smokers with normal activity alleles \[[@CR38]\]. With respect to smoking initiation, adolescents with slower activity alleles may progress to nicotine dependence more slowly than normal metabolizers \[[@CR38]\]. Very recently, researchers reported that *CYP2A6* slow metabolism was associated with increased adolescent smoking cessation in Caucasian individuals \[[@CR39]\]. The ORs for current smoking are reportedly higher in *COMT* rs4680 G/G (the high activity allele) carriers than in those possessing the *COMT* rs4680 variant among healthy Caucasian men of Croatian origin \[[@CR40]\], Americans of European ancestry \[[@CR41]\], and Japanese men \[[@CR15]\]. On the other hand, the *COMT* rs4680 variation (G/A or A/A, the low-activity alleles) was associated with nicotine dependence in men and women of African-American and European-American descent \[[@CR9]\], smoking severity among Chinese male smokers \[[@CR42]\], heaviness of smoking in Caucasian pregnant women \[[@CR43]\], and susceptibility to cigarette smoking among Thai males \[[@CR11]\]. Our results demonstrate for the first time that the combination of the low-activity *CYP2A6* genotype and low-activity *COMT* genotype is associated with the risk of starting smoking.

We also found that the adjusted urinary cotinine concentration was higher in subjects with low-activity *COMT* genes than in those with high-activity *COMT* genes. Additionally, it was higher in subjects with the *COMT* rs4680 variant/*COMT* rs165599 variant than in those with the *COMT* rs4680 wild-type/*COMT* rs165599 variant. The urinary cotinine concentration is a reliable easy-to-use marker for plasma levels of cotinine and the sum of nicotine metabolites in smokers \[[@CR44]\]. Therefore, our findings indicate that cotinine and the sum of nicotine metabolites are metabolized more slowly in subjects carrying the low-activity genotype than in those possessing the high-activity genotype. However, such a difference did not affect FTND, PCDS, or CWS-21 scores, and it was not related to the risk of heavier smoking. The smoking intensity of the university students was lower (average cigarettes/day = 10 and average FTND score = 3.7) than that of Taiwanese adult smokers, e.g., average cigarettes/day = 24 and average FTND score = 7.1 for Chinese adults \[[@CR42]\]. This finding may be the reason, at least in part, that the low activity genotypes of *CYP2A6* and *COMT* were associated with high nicotine dependence scores and heavier smoking, as we reported in this study. For Taiwanese university students, the primary reason for the first contact with smoking was curiosity. Anxiety, avoiding stress, and the difficulties of smoking cessation explained continuing smoking behavior among university students \[[@CR45]\]. The environmental factors may be more predominant than certain genetic factors (e.g., polymorphisms of *CYP2A6* and *COMT* genes) among Taiwanese smokers in the university setting.

There are several limitations to our study. The percentage of female smokers in the Taiwanese population is low, only 4.4%, and they are difficult to recruit as participants. In our report, study participation was restricted to young male Taiwanese smokers. Although the total number of study subjects was relatively large, the numbers of individuals with some of the genotypes were too small to reach statistically significant power. Therefore, further studies with a larger sample size and that include female smokers are needed.

Conclusions {#Sec10}
===========

A single nucleotide polymorphism (rs4680) in the *COMT* gene and the interaction between the *CYP2A6* and *COMT* genes affect smoking status in young Taiwanese men. Effective smoking prevention and cessation intervention programs are required to reduce smoking among university students \[[@CR46]\]. We found that the interaction of the low-activity *CYP2A6* genotype and low-activity *COMT* genotype is associated with the risk of starting smoking. In addition, interaction of the *DRD2* TaqIB and *MAOA* genes also affects smoking intensity in Taiwanese young men \[[@CR14]\]. This knowledge is useful for developing an approach to reducing smoking among Taiwanese university students. A clearer understanding of the relative roles of genetic and non-genetic factors in the initiation of smoking could have implications for the design of smoking prevention programs \[[@CR47]\].
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================
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:   Fagerstrom Test for Nicotine Dependence
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